Breakthrough Treatment for Rare Genetic Disorder Unveiled in New England Journal of Medicine Study
In this week’s New England Journal of Medicine, researchers reveal a paradigm shift in prostate cancer care: a novel perioperative androgen receptor (AR) degrader—apalutamide (brand name Erleada), now FDA-approved for ... Read More